A breakthrough blood test offering a near 100% accuracy in diagnosing chronic fatigue has been announced.
Millions worldwide suffer from ME/CFS, a devastating, long-term condition characterized by profound fatigue not relieved by rest and worsened by exertion, known as post-exertional malaise. Currently, diagnosis relies solely on symptom assessment and ruling out other conditions, often leaving patients in diagnostic limbo.
Chronic fatigue syndrome and long COVID can be deeply debilitating. Pic: Sky News
This new diagnostic blood test for chronic fatigue syndrome, utilizing cutting-edge genomic technology, promises to fundamentally change that frustrating journey, offering clarity and earlier therapeutic intervention.
AD: Capeesh Restaurant
The new test, powered by OBD’s proprietary EpiSwitch 3D Genomics technology, examines epigenetic markers. The DNA within our cells is tightly folded, and these folds determine which genes are active. Researchers discovered that individuals with ME/CFS exhibit a unique, tell-tale pattern in these epigenetic markers, a pattern that is not determined by fixed genetic code but rather influenced by life events. Scientists leveraged this distinct pattern to create the reliable diagnostic tool.
Professor Dmitry Pshezhetskiy, the lead researcher from UEA’s Norwich Medical School, emphasized the test’s significance. “For the first time, we possess a simple blood test able to reliably identify ME/CFS, potentially transforming disease management,” he noted, highlighting the validation this brings to patients frequently dismissed by the medical community.
The trial results showed the test boasts an exceptional 92% sensitivity—the ability to correctly identify ME/CFS patients—and a 98% specificity, correctly ruling out healthy controls. This high performance suggests a game-changer for a disease that many previously dismissed as psychosomatic.
AD: Oysterian Sea Food Restaurant And Bar
Furthermore, the researchers hope this same methodology will pave the way for a similar diagnostic tool to help pinpoint cases of Long COVID, a condition sharing many overlapping symptoms with ME/CFS. The full details of the study are now available in the scientific publication, the Journal of Translational Medicine.
While the findings offer profound hope, the broader medical community urges caution and meticulous further investigation. Professor Chris Ponting of the University of Edinburgh, an expert not affiliated with the study, pointed out that the test needs full validation through better-designed, independent trials.
Critics worry about the current study’s use of controls and the lack of differentiation from other chronic inflammatory diseases, which could lead to misapplication. Additionally, if introduced commercially, the test may cost patients upwards of £1,000, creating accessibility barriers.
The diagnostic blood test for chronic fatigue syndrome remains a massive breakthrough, but its widespread clinical use will require comprehensive, successful replication across larger and more diverse patient groups to secure universal medical acceptance.
AD: Heritage And Restaurant Lounge Bar
